<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">31991108</PMID><DateCompleted><Year>2021</Year><Month>04</Month><Day>06</Day></DateCompleted><DateRevised><Year>2021</Year><Month>04</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1525-0024</ISSN><JournalIssue CitedMedium="Internet"><Volume>28</Volume><Issue>4</Issue><PubDate><Year>2020</Year><Month>Apr</Month><Day>08</Day></PubDate></JournalIssue><Title>Molecular therapy : the journal of the American Society of Gene Therapy</Title><ISOAbbreviation>Mol Ther</ISOAbbreviation></Journal><ArticleTitle>Treatment of a Mouse Model of ALS by In&#xa0;Vivo Base Editing.</ArticleTitle><Pagination><StartPage>1177</StartPage><EndPage>1189</EndPage><MedlinePgn>1177-1189</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ymthe.2020.01.005</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1525-0016(20)30011-3</ELocationID><Abstract><AbstractText>Amyotrophic lateral sclerosis (ALS) is a debilitating and fatal disorder that can be caused by mutations in the superoxide dismutase 1 (SOD1) gene. Although ALS is currently incurable, CRISPR base editors hold the potential to treat the disease through their ability to create nonsense mutations that can&#xa0;permanently disable the expression of the mutant SOD1 gene. However, the restrictive carrying capacity of adeno-associated virus (AAV) vectors has limited their therapeutic application. In this study, we establish an intein-mediated trans-splicing system that enables in&#xa0;vivo delivery of cytidine base editors (CBEs) consisting of the widely used Cas9 protein from Streptococcus pyogenes. We show that intrathecal injection of dual AAV particles encoding a split-intein CBE engineered to trans-splice and introduce a nonsense-coding substitution into a mutant SOD1 gene prolonged survival and markedly slowed the progression of disease in the G93A-SOD1 mouse model of ALS. Adult animals treated by this split-intein CRISPR base editor had a reduced rate of muscle atrophy, decreased muscle denervation, improved neuromuscular function, and up to 40% fewer SOD1 immunoreactive inclusions at end-stage mice compared to control mice. This work expands the capabilities of single-base editors and demonstrates their potential for gene therapy.</AbstractText><CopyrightInformation>Copyright &#xa9; 2020 The American Society of Gene and Cell Therapy. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lim</LastName><ForeName>Colin K W</ForeName><Initials>CKW</Initials><AffiliationInfo><Affiliation>Department of Bioengineering, University of Illinois, Urbana, IL 61801, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gapinske</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Bioengineering, University of Illinois, Urbana, IL 61801, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brooks</LastName><ForeName>Alexandra K</ForeName><Initials>AK</Initials><AffiliationInfo><Affiliation>Department of Bioengineering, University of Illinois, Urbana, IL 61801, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Woods</LastName><ForeName>Wendy S</ForeName><Initials>WS</Initials><AffiliationInfo><Affiliation>Department of Bioengineering, University of Illinois, Urbana, IL 61801, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Powell</LastName><ForeName>Jackson E</ForeName><Initials>JE</Initials><AffiliationInfo><Affiliation>Department of Bioengineering, University of Illinois, Urbana, IL 61801, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zeballos C</LastName><ForeName>M Alejandra</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Department of Bioengineering, University of Illinois, Urbana, IL 61801, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Winter</LastName><ForeName>Jackson</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Bioengineering, University of Illinois, Urbana, IL 61801, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Perez-Pinera</LastName><ForeName>Pablo</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Bioengineering, University of Illinois, Urbana, IL 61801, USA; Carl R. Woese Institute for Genomic Biology, University of Illinois, Urbana, IL 61801, USA; Department of Biomedical and Translational Sciences, Carle-Illinois College of Medicine, University of Illinois, Urbana, IL 61801, USA; Cancer Center at Illinois, University of Illinois, Urbana, IL 61801, USA. Electronic address: pablo@illinois.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gaj</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Bioengineering, University of Illinois, Urbana, IL 61801, USA; Carl R. Woese Institute for Genomic Biology, University of Illinois, Urbana, IL 61801, USA. Electronic address: gaj@illinois.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 GM127497</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>01</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Mol Ther</MedlineTA><NlmUniqueID>100890581</NlmUniqueID><ISSNLinking>1525-0016</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018389">Codon, Nonsense</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="C000606291">Sod1 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="D000072105">Superoxide Dismutase-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.1.-</RegistryNumber><NameOfSubstance UI="D000076987">CRISPR-Associated Protein 9</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000076987" MajorTopicYN="N">CRISPR-Associated Protein 9</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018389" MajorTopicYN="N">Codon, Nonsense</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000229" MajorTopicYN="N">Dependovirus</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000072669" MajorTopicYN="N">Gene Editing</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005822" MajorTopicYN="N">Genetic Vectors</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057809" MajorTopicYN="N">HEK293 Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007278" MajorTopicYN="N">Injections, Spinal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D047668" MajorTopicYN="N">Inteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013297" MajorTopicYN="N">Streptococcus pyogenes</DescriptorName><QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000072105" MajorTopicYN="N">Superoxide Dismutase-1</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020040" MajorTopicYN="N">Trans-Splicing</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">AAV</Keyword><Keyword MajorTopicYN="N">ALS</Keyword><Keyword MajorTopicYN="N">CRISPR-Cas9</Keyword><Keyword MajorTopicYN="N">SOD1</Keyword><Keyword MajorTopicYN="N">base editor</Keyword><Keyword MajorTopicYN="N">gene editing</Keyword><Keyword MajorTopicYN="N">gene therapy</Keyword><Keyword MajorTopicYN="N">neurodegeneration</Keyword><Keyword MajorTopicYN="N">split intein</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>11</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>1</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>1</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>1</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>4</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>1</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31991108</ArticleId><ArticleId IdType="pmc">PMC7132599</ArticleId><ArticleId IdType="doi">10.1016/j.ymthe.2020.01.005</ArticleId><ArticleId IdType="pii">S1525-0016(20)30011-3</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Rowland L.P., Shneider N.A. Amyotrophic lateral sclerosis. N.&#xa0;Engl. J. Med. 2001;344:1688&#x2013;1700.</Citation><ArticleIdList><ArticleId IdType="pubmed">11386269</ArticleId></ArticleIdList></Reference><Reference><Citation>Bensimon G., Lacomblez L., Meininger V., ALS/Riluzole Study Group A controlled trial of riluzole in amyotrophic lateral sclerosis. N.&#xa0;Engl. J. Med. 1994;330:585&#x2013;591.</Citation><ArticleIdList><ArticleId IdType="pubmed">8302340</ArticleId></ArticleIdList></Reference><Reference><Citation>Abe K., Aoki M., Tsuji S., Itoyama Y., Sobue G., Togo M., Writing Group. Edaravone (MCI-186) ALS 19 Study Group Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2017;16:505&#x2013;512.</Citation><ArticleIdList><ArticleId IdType="pubmed">28522181</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosen D.R., Siddique T., Patterson D., Figlewicz D.A., Sapp P., Hentati A., Donaldson D., Goto J., O&#x2019;Regan J.P., Deng H.X. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature. 1993;362:59&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pubmed">8446170</ArticleId></ArticleIdList></Reference><Reference><Citation>Boill&#xe9;e S., Yamanaka K., Lobsiger C.S., Copeland N.G., Jenkins N.A., Kassiotis G., Kollias G., Cleveland D.W. Onset and progression in inherited ALS determined by motor neurons and microglia. Science. 2006;312:1389&#x2013;1392.</Citation><ArticleIdList><ArticleId IdType="pubmed">16741123</ArticleId></ArticleIdList></Reference><Reference><Citation>Haidet-Phillips A.M., Hester M.E., Miranda C.J., Meyer K., Braun L., Frakes A., Song S., Likhite S., Murtha M.J., Foust K.D. Astrocytes from familial and sporadic ALS patients are toxic to motor neurons. Nat. Biotechnol. 2011;29:824&#x2013;828.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3170425</ArticleId><ArticleId IdType="pubmed">21832997</ArticleId></ArticleIdList></Reference><Reference><Citation>Marchetto M.C., Muotri A.R., Mu Y., Smith A.M., Cezar G.G., Gage F.H. Non-cell-autonomous effect of human SOD1G37R astrocytes on motor neurons derived from human embryonic stem cells. Cell Stem Cell. 2008;3:649&#x2013;657.</Citation><ArticleIdList><ArticleId IdType="pubmed">19041781</ArticleId></ArticleIdList></Reference><Reference><Citation>Song S., Miranda C.J., Braun L., Meyer K., Frakes A.E., Ferraiuolo L., Likhite S., Bevan A.K., Foust K.D., McConnell M.J. Major histocompatibility complex class I molecules protect motor neurons from astrocyte-induced toxicity in amyotrophic lateral sclerosis. Nat. Med. 2016;22:397&#x2013;403.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4823173</ArticleId><ArticleId IdType="pubmed">26928464</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamanaka K., Chun S.J., Boillee S., Fujimori-Tonou N., Yamashita H., Gutmann D.H., Takahashi R., Misawa H., Cleveland D.W. Astrocytes as determinants of disease progression in inherited amyotrophic lateral sclerosis. Nat. Neurosci. 2008;11:251&#x2013;253.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3137510</ArticleId><ArticleId IdType="pubmed">18246065</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagai M., Re D.B., Nagata T., Chalazonitis A., Jessell T.M., Wichterle H., Przedborski S. Astrocytes expressing ALS-linked mutated SOD1 release factors selectively toxic to motor neurons. Nat. Neurosci. 2007;10:615&#x2013;622.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3799799</ArticleId><ArticleId IdType="pubmed">17435755</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Giorgio F.P., Boulting G.L., Bobrowicz S., Eggan K.C. Human embryonic stem cell-derived motor neurons are sensitive to the toxic effect of glial cells carrying an ALS-causing mutation. Cell Stem Cell. 2008;3:637&#x2013;648.</Citation><ArticleIdList><ArticleId IdType="pubmed">19041780</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang S.H., Li Y., Fukaya M., Lorenzini I., Cleveland D.W., Ostrow L.W., Rothstein J.D., Bergles D.E. Degeneration and impaired regeneration of gray matter oligodendrocytes in amyotrophic lateral sclerosis. Nat. Neurosci. 2013;16:571&#x2013;579.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3637847</ArticleId><ArticleId IdType="pubmed">23542689</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith R.A., Miller T.M., Yamanaka K., Monia B.P., Condon T.P., Hung G., Lobsiger C.S., Ward C.M., McAlonis-Downes M., Wei H. Antisense oligonucleotide therapy for neurodegenerative disease. J.&#xa0;Clin. Invest. 2006;116:2290&#x2013;2296.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1518790</ArticleId><ArticleId IdType="pubmed">16878173</ArticleId></ArticleIdList></Reference><Reference><Citation>Nizzardo M., Simone C., Rizzo F., Ulzi G., Ramirez A., Rizzuti M., Bordoni A., Bucchia M., Gatti S., Bresolin N. Morpholino-mediated SOD1 reduction ameliorates an amyotrophic lateral sclerosis disease phenotype. Sci. Rep. 2016;6:21301.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4754711</ArticleId><ArticleId IdType="pubmed">26878886</ArticleId></ArticleIdList></Reference><Reference><Citation>Raoul C., Abbas-Terki T., Bensadoun J.C., Guillot S., Haase G., Szulc J., Henderson C.E., Aebischer P. Lentiviral-mediated silencing of SOD1 through RNA interference retards disease onset and progression in a mouse model of ALS. Nat. Med. 2005;11:423&#x2013;428.</Citation><ArticleIdList><ArticleId IdType="pubmed">15768028</ArticleId></ArticleIdList></Reference><Reference><Citation>Foust K.D., Salazar D.L., Likhite S., Ferraiuolo L., Ditsworth D., Ilieva H., Meyer K., Schmelzer L., Braun L., Cleveland D.W., Kaspar B.K. Therapeutic AAV9-mediated suppression of mutant SOD1 slows disease progression and extends survival in models of inherited ALS. Mol. Ther. 2013;21:2148&#x2013;2159.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3863799</ArticleId><ArticleId IdType="pubmed">24008656</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller T.M., Kaspar B.K., Kops G.J., Yamanaka K., Christian L.J., Gage F.H., Cleveland D.W. Virus-delivered small RNA silencing sustains strength in amyotrophic lateral sclerosis. Ann. Neurol. 2005;57:773&#x2013;776.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1351126</ArticleId><ArticleId IdType="pubmed">15852369</ArticleId></ArticleIdList></Reference><Reference><Citation>Dirren E., Aebischer J., Rochat C., Towne C., Schneider B.L., Aebischer P. SOD1 silencing in motoneurons or glia rescues neuromuscular function in ALS mice. Ann. Clin. Transl. Neurol. 2015;2:167&#x2013;184.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4338957</ArticleId><ArticleId IdType="pubmed">25750921</ArticleId></ArticleIdList></Reference><Reference><Citation>Borel F., Gernoux G., Cardozo B., Metterville J.P., Toro Cabrera G.C., Song L., Su Q., Gao G.P., Elmallah M.K., Brown R.H., Jr., Mueller C. Therapeutic rAAVrh10 mediated SOD1 silencing in adult SOD1G93A mice and nonhuman primates. Hum. Gene Ther. 2016;27:19&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4741242</ArticleId><ArticleId IdType="pubmed">26710998</ArticleId></ArticleIdList></Reference><Reference><Citation>Stoica L., Todeasa S.H., Cabrera G.T., Salameh J.S., ElMallah M.K., Mueller C., Brown R.H., Jr., Sena-Esteves M. Adeno-associated virus-delivered artificial microRNA extends survival and delays paralysis in an amyotrophic lateral sclerosis mouse model. Ann. Neurol. 2016;79:687&#x2013;700.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5374859</ArticleId><ArticleId IdType="pubmed">26891182</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomsen G.M., Gowing G., Latter J., Chen M., Vit J.P., Staggenborg K., Avalos P., Alkaslasi M., Ferraiuolo L., Likhite S. Delayed disease onset and extended survival in the SOD1G93A rat model of amyotrophic lateral sclerosis after suppression of mutant SOD1 in the motor cortex. J.&#xa0;Neurosci. 2014;34:15587&#x2013;15600.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4298650</ArticleId><ArticleId IdType="pubmed">25411487</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang H., Yang B., Qiu L., Yang C., Kramer J., Su Q., Guo Y., Brown R.H., Jr., Gao G., Xu Z. Widespread spinal cord transduction by intrathecal injection of rAAV delivers efficacious RNAi therapy for amyotrophic lateral sclerosis. Hum. Mol. Genet. 2014;23:668&#x2013;681.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3888258</ArticleId><ArticleId IdType="pubmed">24108104</ArticleId></ArticleIdList></Reference><Reference><Citation>Biferi M.G., Cohen-Tannoudji M., Cappelletto A., Giroux B., Roda M., Astord S., Marais T., Bos C., Voit T., Ferry A., Barkats M. A new AAV10-U7-mediated gene therapy prolongs survival and restores function in an ALS mouse model. Mol. Ther. 2017;25:2038&#x2013;2052.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5589057</ArticleId><ArticleId IdType="pubmed">28663100</ArticleId></ArticleIdList></Reference><Reference><Citation>Iannitti T., Scarrott J.M., Likhite S., Coldicott I.R.P., Lewis K.E., Heath P.R., Higginbottom A., Myszczynska M.A., Milo M., Hautbergue G.M. Translating SOD1 gene silencing toward the clinic: a highly efficacious, off-target-free, and biomarker-supported strategy for fALS. Mol. Ther. Nucleic Acids. 2018;12:75&#x2013;88.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6023790</ArticleId><ArticleId IdType="pubmed">30195799</ArticleId></ArticleIdList></Reference><Reference><Citation>Jinek M., Chylinski K., Fonfara I., Hauer M., Doudna J.A., Charpentier E. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science. 2012;337:816&#x2013;821.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6286148</ArticleId><ArticleId IdType="pubmed">22745249</ArticleId></ArticleIdList></Reference><Reference><Citation>Cong L., Ran F.A., Cox D., Lin S., Barretto R., Habib N., Hsu P.D., Wu X., Jiang W., Marraffini L.A., Zhang F. Multiplex genome engineering using CRISPR/Cas systems. Science. 2013;339:819&#x2013;823.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3795411</ArticleId><ArticleId IdType="pubmed">23287718</ArticleId></ArticleIdList></Reference><Reference><Citation>Mali P., Yang L., Esvelt K.M., Aach J., Guell M., DiCarlo J.E., Norville J.E., Church G.M. RNA-guided human genome engineering via Cas9. Science. 2013;339:823&#x2013;826.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3712628</ArticleId><ArticleId IdType="pubmed">23287722</ArticleId></ArticleIdList></Reference><Reference><Citation>Jinek M., East A., Cheng A., Lin S., Ma E., Doudna J. RNA-programmed genome editing in human cells. eLife. 2013;2:e00471.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3557905</ArticleId><ArticleId IdType="pubmed">23386978</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaj T., Ojala D.S., Ekman F.K., Byrne L.C., Limsirichai P., Schaffer D.V. In&#xa0;vivo genome editing improves motor function and extends survival in a mouse model of ALS. Sci. Adv. 2017;3 eaar3952.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5738228</ArticleId><ArticleId IdType="pubmed">29279867</ArticleId></ArticleIdList></Reference><Reference><Citation>Kosicki M., Tomberg K., Bradley A. Repair of double-strand breaks induced by CRISPR-Cas9 leads to large deletions and complex rearrangements. Nat. Biotechnol. 2018;36:765&#x2013;771.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6390938</ArticleId><ArticleId IdType="pubmed">30010673</ArticleId></ArticleIdList></Reference><Reference><Citation>Mou H., Smith J.L., Peng L., Yin H., Moore J., Zhang X.O., Song C.Q., Sheel A., Wu Q., Ozata D.M. CRISPR/Cas9-mediated genome editing induces exon skipping by alternative splicing or exon deletion. Genome Biol. 2017;18:108.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5470253</ArticleId><ArticleId IdType="pubmed">28615073</ArticleId></ArticleIdList></Reference><Reference><Citation>Rees H.A., Liu D.R. Base editing: precision chemistry on the genome and transcriptome of living cells. Nat. Rev. Genet. 2018;19:770&#x2013;788.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6535181</ArticleId><ArticleId IdType="pubmed">30323312</ArticleId></ArticleIdList></Reference><Reference><Citation>Komor A.C., Kim Y.B., Packer M.S., Zuris J.A., Liu D.R. Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage. Nature. 2016;533:420&#x2013;424.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4873371</ArticleId><ArticleId IdType="pubmed">27096365</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaudelli N.M., Komor A.C., Rees H.A., Packer M.S., Badran A.H., Bryson D.I., Liu D.R. Programmable base editing of A&#x2022;T to G&#x2022;C in genomic DNA without DNA cleavage. Nature. 2017;551:464&#x2013;471.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5726555</ArticleId><ArticleId IdType="pubmed">29160308</ArticleId></ArticleIdList></Reference><Reference><Citation>Iyama T., Wilson D.M., 3rd DNA repair mechanisms in dividing and non-dividing cells. DNA Repair (Amst.) 2013;12:620&#x2013;636.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3720834</ArticleId><ArticleId IdType="pubmed">23684800</ArticleId></ArticleIdList></Reference><Reference><Citation>Yeh W.H., Chiang H., Rees H.A., Edge A.S.B., Liu D.R. In&#xa0;vivo base editing of post-mitotic sensory cells. Nat. Commun. 2018;9:2184.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5988727</ArticleId><ArticleId IdType="pubmed">29872041</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuscu C., Parlak M., Tufan T., Yang J., Szlachta K., Wei X., Mammadov R., Adli M. CRISPR-STOP: gene silencing through base-editing-induced nonsense mutations. Nat. Methods. 2017;14:710&#x2013;712.</Citation><ArticleIdList><ArticleId IdType="pubmed">28581493</ArticleId></ArticleIdList></Reference><Reference><Citation>Billon P., Bryant E.E., Joseph S.A., Nambiar T.S., Hayward S.B., Rothstein R., Ciccia A. CRISPR-mediated base editing enables efficient disruption of eukaryotic genes through induction of STOP codons. Mol. Cell. 2017;67:1068&#x2013;1079.e4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5610906</ArticleId><ArticleId IdType="pubmed">28890334</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim Y.B., Komor A.C., Levy J.M., Packer M.S., Zhao K.T., Liu D.R. Increasing the genome-targeting scope and precision of base editing with engineered Cas9-cytidine deaminase fusions. Nat. Biotechnol. 2017;35:371&#x2013;376.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5388574</ArticleId><ArticleId IdType="pubmed">28191901</ArticleId></ArticleIdList></Reference><Reference><Citation>Kleinstiver B.P., Prew M.S., Tsai S.Q., Nguyen N.T., Topkar V.V., Zheng Z., Joung J.K. Broadening the targeting range of Staphylococcus aureus CRISPR-Cas9 by modifying PAM recognition. Nat. Biotechnol. 2015;33:1293&#x2013;1298.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4689141</ArticleId><ArticleId IdType="pubmed">26524662</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller T.M., Pestronk A., David W., Rothstein J., Simpson E., Appel S.H., Andres P.L., Mahoney K., Allred P., Alexander K. An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: a phase 1, randomised, first-in-man study. Lancet Neurol. 2013;12:435&#x2013;442.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3712285</ArticleId><ArticleId IdType="pubmed">23541756</ArticleId></ArticleIdList></Reference><Reference><Citation>High K.A., Roncarolo M.G. Gene therapy. N.&#xa0;Engl. J. Med. 2019;381:455&#x2013;464.</Citation><ArticleIdList><ArticleId IdType="pubmed">31365802</ArticleId></ArticleIdList></Reference><Reference><Citation>Mendell J.R., Al-Zaidy S., Shell R., Arnold W.D., Rodino-Klapac L.R., Prior T.W., Lowes L., Alfano L., Berry K., Church K. Single-dose gene-replacement therapy for spinal muscular atrophy. N.&#xa0;Engl. J. Med. 2017;377:1713&#x2013;1722.</Citation><ArticleIdList><ArticleId IdType="pubmed">29091557</ArticleId></ArticleIdList></Reference><Reference><Citation>Borel F., Gernoux G., Sun H., Stock R., Blackwood M., Brown R.H., Jr., Mueller C. Safe and effective superoxide dismutase 1 silencing using artificial microRNA in macaques. Sci. Transl. Med. 2018;10:eaau6414.</Citation><ArticleIdList><ArticleId IdType="pubmed">30381409</ArticleId></ArticleIdList></Reference><Reference><Citation>Hudry E., Vandenberghe L.H. Therapeutic AAV gene transfer to the nervous system: a clinical reality. Neuron. 2019;102:263.</Citation><ArticleIdList><ArticleId IdType="pubmed">30946822</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaj T., Epstein B.E., Schaffer D.V. Genome engineering using adeno-associated virus: basic and clinical research applications. Mol. Ther. 2016;24:458&#x2013;464.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4786909</ArticleId><ArticleId IdType="pubmed">26373345</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu X.Q., Hu Z. A DnaB intein in Rhodothermus marinus: indication of recent intein homing across remotely related organisms. Proc. Natl. Acad. Sci. USA. 1997;94:7851&#x2013;7856.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC21518</ArticleId><ArticleId IdType="pubmed">9223276</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishimasu H., Ran F.A., Hsu P.D., Konermann S., Shehata S.I., Dohmae N., Ishitani R., Zhang F., Nureki O. Crystal structure of Cas9 in complex with guide RNA and target DNA. Cell. 2014;156:935&#x2013;949.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4139937</ArticleId><ArticleId IdType="pubmed">24529477</ArticleId></ArticleIdList></Reference><Reference><Citation>Villiger L., Grisch-Chan H.M., Lindsay H., Ringnalda F., Pogliano C.B., Allegri G., Fingerhut R., H&#xe4;berle J., Matos J., Robinson M.D. Treatment of a metabolic liver disease by in&#xa0;vivo genome base editing in adult mice. Nat. Med. 2018;24:1519&#x2013;1525.</Citation><ArticleIdList><ArticleId IdType="pubmed">30297904</ArticleId></ArticleIdList></Reference><Reference><Citation>Gapinske M., Luu A., Winter J., Woods W.S., Kostan K.A., Shiva N., Song J.S., Perez-Pinera P. CRISPR-SKIP: programmable gene splicing with single base editors. Genome Biol. 2018;19:107.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6092781</ArticleId><ArticleId IdType="pubmed">30107853</ArticleId></ArticleIdList></Reference><Reference><Citation>Gurney M.E., Pu H., Chiu A.Y., Dal Canto M.C., Polchow C.Y., Alexander D.D., Caliendo J., Hentati A., Kwon Y.W., Deng H.X. Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation. Science. 1994;264:1772&#x2013;1775.</Citation><ArticleIdList><ArticleId IdType="pubmed">8209258</ArticleId></ArticleIdList></Reference><Reference><Citation>Vinsant S., Mansfield C., Jimenez-Moreno R., Del Gaizo Moore V., Yoshikawa M., Hampton T.G., Prevette D., Caress J., Oppenheim R.W., Milligan C. Characterization of early pathogenesis in the SOD1G93A mouse model of ALS: part II, results and discussion. Brain Behav. 2013;3:431&#x2013;457.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3869683</ArticleId><ArticleId IdType="pubmed">24381813</ArticleId></ArticleIdList></Reference><Reference><Citation>Bey K., Ciron C., Dubreil L., Deniaud J., Ledevin M., Cristini J., Blouin V., Aubourg P., Colle M.A. Efficient CNS targeting in adult mice by intrathecal infusion of single-stranded AAV9-GFP for gene therapy of neurological disorders. Gene Ther. 2017;24:325&#x2013;332.</Citation><ArticleIdList><ArticleId IdType="pubmed">28425480</ArticleId></ArticleIdList></Reference><Reference><Citation>Gong Y., Berenson A., Laheji F., Gao G., Wang D., Ng C., Volak A., Kok R., Kreouzis V., Dijkstra I.M. Intrathecal adeno-associated viral vector-mediated gene delivery for adrenomyeloneuropathy. Hum. Gene Ther. 2019;30:544&#x2013;555.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6909708</ArticleId><ArticleId IdType="pubmed">30358470</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang L., Gutmann D.H., Roos R.P. Astrocyte loss of mutant SOD1 delays ALS disease onset and progression in G85R transgenic mice. Hum. Mol. Genet. 2011;20:286&#x2013;293.</Citation><ArticleIdList><ArticleId IdType="pubmed">20962037</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks A.K., Gaj T. Innovations in CRISPR technology. Curr. Opin. Biotechnol. 2018;52:95&#x2013;101.</Citation><ArticleIdList><ArticleId IdType="pubmed">29626736</ArticleId></ArticleIdList></Reference><Reference><Citation>Winter J., Luu A., Gapinske M., Manandhar S., Shirguppe S., Woods W.S., Song J.S., Perez-Pinera P. Targeted exon skipping with AAV-mediated split adenine base editors. Cell Discov. 2019;5:41.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6796986</ArticleId><ArticleId IdType="pubmed">31636954</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryu S.M., Koo T., Kim K., Lim K., Baek G., Kim S.T., Kim H.S., Kim D.E., Lee H., Chung E., Kim J.S. Adenine base editing in mouse embryos and an adult mouse model of Duchenne muscular dystrophy. Nat. Biotechnol. 2018;36:536&#x2013;539.</Citation><ArticleIdList><ArticleId IdType="pubmed">29702637</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin S., Zong Y., Gao Q., Zhu Z., Wang Y., Qin P., Liang C., Wang D., Qiu J.L., Zhang F., Gao C. Cytosine, but not adenine, base editors induce genome-wide off-target mutations in rice. Science. 2019;364:292&#x2013;295.</Citation><ArticleIdList><ArticleId IdType="pubmed">30819931</ArticleId></ArticleIdList></Reference><Reference><Citation>Zuo E., Sun Y., Wei W., Yuan T., Ying W., Sun H., Yuan L., Steinmetz L.M., Li Y., Yang H. Cytosine base editor generates substantial off-target single-nucleotide variants in mouse embryos. Science. 2019;364:289&#x2013;292.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7301308</ArticleId><ArticleId IdType="pubmed">30819928</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou C., Sun Y., Yan R., Liu Y., Zuo E., Gu C., Han L., Wei Y., Hu X., Zeng R. Off-target RNA mutation induced by DNA base editing and its elimination by mutagenesis. Nature. 2019;571:275&#x2013;278.</Citation><ArticleIdList><ArticleId IdType="pubmed">31181567</ArticleId></ArticleIdList></Reference><Reference><Citation>Gr&#xfc;newald J., Zhou R., Garcia S.P., Iyer S., Lareau C.A., Aryee M.J., Joung J.K. Transcriptome-wide off-target RNA editing induced by CRISPR-guided DNA base editors. Nature. 2019;569:433&#x2013;437.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6657343</ArticleId><ArticleId IdType="pubmed">30995674</ArticleId></ArticleIdList></Reference><Reference><Citation>Chadderton N., Millington-Ward S., Palfi A., O&#x2019;Reilly M., Tuohy G., Humphries M.M., Li T., Humphries P., Kenna P.F., Farrar G.J. Improved retinal function in a mouse model of dominant retinitis pigmentosa following AAV-delivered gene therapy. Mol. Ther. 2009;17:593&#x2013;599.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2835099</ArticleId><ArticleId IdType="pubmed">19174761</ArticleId></ArticleIdList></Reference><Reference><Citation>Cideciyan A.V., Sudharsan R., Dufour V.L., Massengill M.T., Iwabe S., Swider M., Lisi B., Sumaroka A., Marinho L.F., Appelbaum T. Mutation-independent rhodopsin gene therapy by knockdown and replacement with a single AAV vector. Proc. Natl. Acad. Sci. USA. 2018;115:E8547&#x2013;E8556.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6130384</ArticleId><ArticleId IdType="pubmed">30127005</ArticleId></ArticleIdList></Reference><Reference><Citation>Kotterman M.A., Schaffer D.V. Engineering adeno-associated viruses for clinical gene therapy. Nat. Rev. Genet. 2014;15:445&#x2013;451.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4393649</ArticleId><ArticleId IdType="pubmed">24840552</ArticleId></ArticleIdList></Reference><Reference><Citation>Gibson D.G., Young L., Chuang R.Y., Venter J.C., Hutchison C.A., 3rd, Smith H.O. Enzymatic assembly of DNA molecules up to several hundred kilobases. Nat. Methods. 2009;6:343&#x2013;345.</Citation><ArticleIdList><ArticleId IdType="pubmed">19363495</ArticleId></ArticleIdList></Reference><Reference><Citation>Perez-Pinera P., Kocak D.D., Vockley C.M., Adler A.F., Kabadi A.M., Polstein L.R., Thakore P.I., Glass K.A., Ousterout D.G., Leong K.W. RNA-guided gene activation by CRISPR-Cas9-based transcription factors. Nat. Methods. 2013;10:973&#x2013;976.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3911785</ArticleId><ArticleId IdType="pubmed">23892895</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaj T., Schaffer D.V. Adeno-associated virus-mediated delivery of CRISPR&#x2013;Cas systems for genome engineering in mammalian cells. Cold Spring Harb. Protoc. 2016. 2016 prot086868.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6850213</ArticleId><ArticleId IdType="pubmed">27803249</ArticleId></ArticleIdList></Reference><Reference><Citation>Langmead B., Salzberg S.L. Fast gapped-read alignment with Bowtie 2. Nat. Methods. 2012;9:357&#x2013;359.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3322381</ArticleId><ArticleId IdType="pubmed">22388286</ArticleId></ArticleIdList></Reference><Reference><Citation>Li H., Handsaker B., Wysoker A., Fennell T., Ruan J., Homer N., Marth G., Abecasis G., Durbin R., 1000 Genome Project Data Processing Subgroup The sequence alignment/map format and SAMtools. Bioinformatics. 2009;25:2078&#x2013;2079.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2723002</ArticleId><ArticleId IdType="pubmed">19505943</ArticleId></ArticleIdList></Reference><Reference><Citation>Robinson J.T., Thorvaldsd&#xf3;ttir H., Winckler W., Guttman M., Lander E.S., Getz G., Mesirov J.P. Integrative genomics viewer. Nat. Biotechnol. 2011;29:24&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3346182</ArticleId><ArticleId IdType="pubmed">21221095</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>